Tamsulosin Hydrochloride 0.4 mg Capsules Under Fasting Conditions
Launched by TEVA PHARMACEUTICALS USA · Jun 22, 2010
Trial Information
Current as of May 20, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Healthy, non-smoking male subjects, 18 years of age or older.
- • BMI greater than or equal to 19 and less than or equal to 30.
- * Negative for:
- • HIV.
- • Hepatitis B surface antigen and Hepatitis C antibody.
- • Using drugs of abuse test (marijuana, amphetamines, barbiturates, cocaine, opiates, benzodiazepines and methadone).
- • Urine cotinine test
- • No significant diseases or clinically significant findings in a physical examination.
- • No clinically significant abnormal laboratory values.
- • No clinically significant findings in vital signs measurements and a 12-lead electrocardiogram (ECG).
- • Systolic blood pressure between 100-140 mmHg and diastolic blood pressure between 60-90 mmgHg.
- • Be informed of the nature of the study and given written consent prior to receiving any study procedure.
- Exclusion Criteria:
- • Known history or presence of any clinically significant medical condition, illness or surgery within 4 weeks prior to drug administration.
- • Known or suspected carcinoma.
- * Known history or presence of:
- • Hypersensitivity or idiosyncratic reaction to tamsulosin and/or any other drug substances with similar activity.
- • Alcoholism within the last 12 months.
- • Drug dependence and/or substance abuse.
- • Use of tobacco or nicotine-containing products within the last 6 months.
- • Use of any prescription medication within 14 days prior to Period 1 dosing. Use of any over the counter (OTC) medication within 7 days prior to Period 1 dosing.
- • Use of any drugs known to induce or inhibit hepatic drug metabolism within 30 days prior to Period 1 dosing.
- • On a special diet within 4 weeks prior to drug administration (e.g. liquid, protein, raw food diet).
- • Participated in another clinical trial or received and investigational product within 30 days prior to drug administration.
- • Donated up to 250 mL of blood within the previous 30 days OR Donated from 251 to 500 mL of blood in the previous 45 days OR Donated more than 500 mL of blood in the previous 56 days (based on the Canadian Blood Services guideline for blood donation.
- • Difficulty fasting or consuming the standard meals.
- • Do not tolerate venipuncture.
- • Unable to read or sign the ICF.
About Teva Pharmaceuticals Usa
Teva Pharmaceuticals USA is a leading global pharmaceutical company dedicated to improving patient outcomes through the development and commercialization of innovative medicines. With a strong focus on generics and specialty pharmaceuticals, Teva leverages its extensive research and development capabilities to address pressing healthcare needs across various therapeutic areas, including neurology, oncology, and respiratory conditions. Committed to advancing scientific knowledge and fostering collaborative partnerships, Teva actively conducts clinical trials to evaluate the safety and efficacy of its products, ensuring that they meet the highest standards of quality and regulatory compliance. With a legacy of over a century in the industry, Teva continues to be at the forefront of pharmaceutical innovation, striving to enhance the lives of patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Toronto, Ontario, Canada
Patients applied
Trial Officials
Xueyu (Eric) Chen, M.D., Ph. D., FRCP (C)
Principal Investigator
Pharma Medica Research, Inc.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials